RxDoctor Payments Data

Bonita Miles Mack

Optometrist · Rock Hill, SCNPI 1821218835

Payments from drug & device makers

$3,206in general payments, 2019–2025

Across 63 payments — averaging $50.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$791
  • Johnson & Johnson Vision Care, Inc.$425
  • Bausch & Lomb Americas Inc.$266
  • Biotissue Holdings Inc.$240
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$232
  • AbbVie$227
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,206 in reported general payments places this provider in the 80th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$150,547
Medicare patients
669
Services billed
2,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine48$49,063
LumiganBimatoprost13$9,281
Cyclosporine16$8,900
Brimonidine Tartrate32$1,897
Latanoprost167$1,482
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha102$1,005
Azelastine Hcl28$907
Fluorometholone13$779
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$642
Tobramycin-DexamethasoneTobramycin/Dexamethasone20$570
ErythromycinErythromycin Base36$371
Prednisolone Acetate12$328
Timolol Maleate53$293
Doxycycline Hyclate12$116
Cephalexin17$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$227$58,34461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →